Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-001 in newly diagnosed chronic phase chronic myeloid leukemia
ACTRN12626001253392Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of relcobatinib in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Major molecular response (MMR). Planned start Aug 2027; status: not yet recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12626001253392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001253392.